Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation

Zhihong Zeng; Wenbin Liu; Christopher B. Benton; Sergej Konoplev; Hongbo Lu; Rui Yu Wang; Julianne Chen; Elizabeth Shpall; Keith A. Baggerly; Richard Champlin; Marina Konopleva

doi:10.1159/000495456

Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation

Zhihong Zeng, Wenbin Liu, Christopher B. Benton, Sergej Konoplev, Hongbo Lu, Rui Yu Wang, Julianne Chen, Elizabeth Shpall, Keith A. Baggerly, Richard Champlin, Marina Konopleva

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.

Original language	English (US)
Pages (from-to)	176-184
Number of pages	9
Journal	Acta haematologica
Volume	142
Issue number	3
DOIs	https://doi.org/10.1159/000495456
State	Published - Sep 1 2019

Keywords

Acute myeloid leukemia
Allogeneic stem cell transplantation
CXCR4
Plerixafor
Proteomic profiling of signaling

ASJC Scopus subject areas

Hematology

MD Anderson CCSG core facilities

Bioinformatics Shared Resource
Flow Cytometry and Cellular Imaging Facility
Functional Proteomics Reverse Phase Protein Array Core
Clinical Trials Office

Access to Document

10.1159/000495456

Fingerprint

Dive into the research topics of 'Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation'. Together they form a unique fingerprint.

Cite this

Zeng, Z., Liu, W., Benton, C. B., Konoplev, S., Lu, H., Wang, R. Y., Chen, J., Shpall, E., Baggerly, K. A., Champlin, R., & Konopleva, M. (2019). Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta haematologica, 142(3), 176-184. https://doi.org/10.1159/000495456

Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. / Zeng, Zhihong ; Liu, Wenbin; Benton, Christopher B. et al.
In: Acta haematologica, Vol. 142, No. 3, 01.09.2019, p. 176-184.

Research output: Contribution to journal › Article › peer-review

Zeng, Z , Liu, W, Benton, CB, Konoplev, S, Lu, H, Wang, RY, Chen, J, Shpall, E, Baggerly, KA, Champlin, R & Konopleva, M 2019, 'Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation', Acta haematologica, vol. 142, no. 3, pp. 176-184. https://doi.org/10.1159/000495456

@article{1431d5c9f8e44dd094ef3f5aa44c5459,

title = "Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation",

abstract = "To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.",

keywords = "Acute myeloid leukemia, Allogeneic stem cell transplantation, CXCR4, Plerixafor, Proteomic profiling of signaling",

author = "Zhihong Zeng and Wenbin Liu and Benton, {Christopher B.} and Sergej Konoplev and Hongbo Lu and Wang, {Rui Yu} and Julianne Chen and Elizabeth Shpall and Baggerly, {Keith A.} and Richard Champlin and Marina Konopleva",

note = "Funding Information: This work was supported in part by National Institutes of Health/National Cancer Institute (NIH/NCI) grant No. R21 CA137637, Leukemia and Lymphoma Society grant No. 6427-13 (all to M.K.), and NIH/NCI Cancer Center Support Grant P30 CA016672 (to MD Anderson Cancer Center; used the RPPA Core Facility and Clinical Trials Support Resource). Funding Information: This work was supported in part by National Institutes of Health/National Cancer Institute (NIH/NCI) grant No. R21 CA137637, Leukemia and Lymphoma Society grant No. 6427–13 (all to M.K.), and NIH/NCI Cancer Center Support Grant P30 CA016672 (to MD Anderson Cancer Center; used the RPPA Core Facility and Clinical Trials Support Resource). Publisher Copyright: {\textcopyright} 2019 S. Karger AG, Basel. Copyright: All rights reserved.",

year = "2019",

month = sep,

day = "1",

doi = "10.1159/000495456",

language = "English (US)",

volume = "142",

pages = "176--184",

journal = "Acta haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation

AU - Zeng, Zhihong

AU - Liu, Wenbin

AU - Benton, Christopher B.

AU - Konoplev, Sergej

AU - Lu, Hongbo

AU - Wang, Rui Yu

AU - Chen, Julianne

AU - Shpall, Elizabeth

AU - Baggerly, Keith A.

AU - Champlin, Richard

AU - Konopleva, Marina

N1 - Funding Information: This work was supported in part by National Institutes of Health/National Cancer Institute (NIH/NCI) grant No. R21 CA137637, Leukemia and Lymphoma Society grant No. 6427-13 (all to M.K.), and NIH/NCI Cancer Center Support Grant P30 CA016672 (to MD Anderson Cancer Center; used the RPPA Core Facility and Clinical Trials Support Resource). Funding Information: This work was supported in part by National Institutes of Health/National Cancer Institute (NIH/NCI) grant No. R21 CA137637, Leukemia and Lymphoma Society grant No. 6427–13 (all to M.K.), and NIH/NCI Cancer Center Support Grant P30 CA016672 (to MD Anderson Cancer Center; used the RPPA Core Facility and Clinical Trials Support Resource). Publisher Copyright: © 2019 S. Karger AG, Basel. Copyright: All rights reserved.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.

AB - To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.

KW - Acute myeloid leukemia

KW - Allogeneic stem cell transplantation

KW - CXCR4

KW - Plerixafor

KW - Proteomic profiling of signaling

UR - http://www.scopus.com/inward/record.url?scp=85066911622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066911622&partnerID=8YFLogxK

U2 - 10.1159/000495456

DO - 10.1159/000495456

M3 - Article

C2 - 31112940

AN - SCOPUS:85066911622

SN - 0001-5792

VL - 142

SP - 176

EP - 184

JO - Acta haematologica

JF - Acta haematologica

IS - 3

ER -

Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this